LEGN Legend Biotech Corp

Nasdaq legendbiotech.com


$ 32.41 $ 0.12 (0.37 %)    

Monday, 03-Nov-2025 09:54:33 EST
QQQ $ 632.49 $ -2.73 (-0.43 %)
DIA $ 473.63 $ -2.51 (-0.53 %)
SPY $ 682.17 $ -3.47 (-0.51 %)
TLT $ 89.71 $ 0.06 (0.07 %)
GLD $ 370.31 $ 1.51 (0.41 %)
$ 32.4
$ 32.45
$ 32.38 x 1
$ 32.42 x 7
$ 32.41 - $ 32.57
$ 27.34 - $ 47.79
1,100,495
na
5.95B
$ 0.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-60

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price ta...

 jp-morgan-maintains-overweight-on-legend-biotech-lowers-price-target-to-76

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 ...

Core News & Articles

Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc.On October 6, 2025...

 legend-biotech-is-said-to-explore-second-listing-outside-of-us--bloomberg

https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us

 cantor-fitzgerald-assumes-legend-biotech-at-overweight-announces-price-target-of-66

Cantor Fitzgerald analyst Eric Schmidt assumes Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Tar...

 jp-morgan-maintains-overweight-on-legend-biotech-raises-price-target-to-78

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $77 ...

 rbc-capital-maintains-outperform-on-legend-biotech-raises-price-target-to-77

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

 morgan-stanley-maintains-overweight-on-legend-biotech-raises-price-target-to-83

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target...

 hc-wainwright--co-reiterates-buy-on-legend-biotech-maintains-75-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $75 price t...

 morgan-stanley-maintains-overweight-on-legend-biotech-raises-price-target-to-81

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION